Rational design and synthesis of potent dibenzazepine motifs as β-secretase inhibitors

Journal of Medicinal Chemistry

Volumn 52, Issue 20, 2009, Pages 6484-6488

  Al Tel, Taleb H ^a   Al Qawasmeh, Raed A ^b   Schmidt, Marco F ^c   Al Aboudi, Amal ^b   Rao, Shashidhar N ^d   Sabri, Salim S ^a   Voelter, Wolfgang ^e  

^a UNIVERSITY OF SHARJAH   (United Arab Emirates)

^b UNIVERSITY OF JORDAN   (Jordan)

^c LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

^d SCHRÖDINGER INC   (United States)

^e UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXO N(PYRIDIN 4 YL) 10,11 DIHYDRO 5H DIBENZO[B,E][1,4]DIAZEPINE 3 CARBOXAMIDE; 3 (3H IMIDAZO[4,5 C]PYRIDIN 2 YL) 5H DIBENZO[B,E][1,4]DIAZEPIN 11 (10H) ONE; 3 [5 (4 FLUOROPHENYL) 1H IMIDAZOL 2 YL] 5H DIBENZO[B,E][1,4]DIAZEPIN 11 (10H) ONE; 3 [5 (PYRIDIN 4 YL) 1H IMIDAZOL 2 YL] 5H DIBENZO[B,E][1,4]DIAZEPIN 11 (10H) ONE; 3 [6 FLUORO 1H BENZO[D]IMIDAZOL 2 YL) 5H DIBENZO[B,E][1,4]DIAZEPIN 11 (10H) ONE; AMIDE; BETA SECRETASE; DIBENZAZEPINE DERIVATIVE; N(4 FLUOROPHENYL) 11 OXO 10,11 DIHYDRO 5H DIBENZO[B,E][1,4]DIAZEPINE 3 CARBOXAMIDE; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG DESIGN; DRUG IDENTIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; FLUORESCENCE RESONANCE ENERGY TRANSFER;

AMIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; DIBENZAZEPINES; DRUG DESIGN; IMIDAZOLES; INHIBITORY CONCENTRATION 50; PHTHALIC ACIDS; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70350048595     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9008482     Document Type: Article

References (21)

1. (a) Cummings, J. L. Alzheimer's Disease. N. Engl. J. Med. 2004, 351, 56-67.
2. (b) Nguyen, J.; Yamani, A.; Kiso, Y. Views on Amyloid Hypothesis and Secretase Inhibitors for Treating Alzheimer's Disease: Progress and Problems. Curr. Pharm. Des. 2006, 12, 4295-4312.
3. (c) For online resources and figures about AD, see www.alz.org and www.ahaf.org.
4. Celsis, P. Age-related cognitive decline, mild cognitive impairment or pre-clinical Alzheimer's disease. Ann. Med. 2000, 32, 6-14.
5. (a) Stavrovskaya, I. G.; Kristal, B. S. The Powerhouse Takes Control of the Cell: Is the Mitochondrial Permeability Transition a Viable Therapeutic Target against Neuronal Dysfunction and Death? Free Radical Biol. Med. 2005, 38, 687-697.
6. (b) Milligan, C. Caspase Cleavage of APP Results in a Cytotoxic Proteolytic Peptide. Nat. Med. 2000, 6, 385-386.
7. Yan, R.; Bienkowski, M. J.; Shuck, M. E.; Miao, H.; Tory, M. C.; Pauley, A. M.; Brashier, J. R.; Stratman, N. C.; Mathews, R. W.; Buhl, A. E.; Carter, D. B.; Tomasselli, A. G.; Parodi, L. A.; Heinrikson, R. L.; Gurney, M. Membrane-Anchored Aspartyl Protease with Alzheimer's Disease Beta-Secretase Activity. Nature 1999, 402, 533-537.
8. (a) Iwatsubo, T.; Odaka, A.; Suzuki, N.; Mizusawa, H.; Nukina, N.; Ihara, Y. Visualization of Aβ42(43) and Aβ40 in Senile Plaques with End-Specific Aβ Monoclonals: Evidence That an Initially Deposited Species Is Aβ42(43). Neuron 1994, 13, 45-53.
9. (b) St George-Hyslop, P. H.; Morris, J. C. Will Anti-Amyloid Therapies Work for Alzheimer's Disease? Lancet 2008, 372, 180-182.
10. (c) Ghosh, A. K.; Bilcer, G.; Hong, L.; Koelsch, G.; Tang, J. Memapsin 2 (Beta-Secretase) Inhibitor Drug, between Fantasy and Reality. Curr. Alzheimer Res. 2007, 4, 418-422.
11. (d) Durham, T. B.; Shepherd, T. A. Progress toward the Discovery and Development of Efficacious BACE Inhibitors. Curr. Opin. Drug Discovery Dev. 2006, 9, 776-791.
12. Wolfe, M. S. Secretase Targets for Alzheimer's Disease: Identification and Therapeutic Potential. J. Med. Chem. 2001, 44, 2039-2060.
13. (a) Willem, M.; Garratt, A. N.; Novak, B.; Citron, M.; Kaufmann, S.; Rittger, A.; DeStrooper, B.; Saftig, P.; Birchmeier, C.; Haass, C. Control of Peripheral Nerve Myelination by the β-Secretase BACE1. Science 2006, 314, 664-666. (Pubitemid 44646394)
14. (a) Stanton, M. G.; Stauffer, S. R.; Gregro, A. R.; Selnick, H. Discovery of Isonicotinamide Derived β-Secretase Inhibitors: In Vivo Reduction of β-Amyloid. J. Med. Chem. 2007, 50, 3431-3433.
15. (b) Charrier, N.; Clarke, B.; Cutler, L.; Demont, E.; Dingwall, C.; Dunsdon, R.; East, P.; Hawkins, J.; Howes, C.; Hussain, I.; Jeffrey, P.; Maile, G.; Matico, R.; Mosley, J.; Naylor, A.; O'Brien, A.; Redshaw, S.; Rowland, P.; Soleil, V.; Smith, K. J.; Sweitzer, S.; Theobald, P.; Vesey, D.;Walter, D. S.;Wayne, G. Second Generation of Hydroxyethylamine BACE-1 Inhibitors: Optimizing Potency and Oral Bioavailability. J. Med. Chem. 2008, 51, 3313-3317.
16. (c) Cumming, J. N.; Le, T. X.; Babu, S.; Carroll, C.; Chen, X.; Favreau, L.; Gaspari, P.; Guo, T.; Hobbs, D. W.; Huang, Y.; Iserloh, U.; Kennedy, M. E.; Kuvelkar, R.; Li, G.; Lowrie, J.; McHugh, N. A.; Ozgur, L.; Pan, J.; Parker, E. M.; Saionz, K.; Stamford, A. W.; Strickland, C.; Tadesse, D.; Voigt, J.; Wang, L.; Wu, Y.; Zhang, L.; Zhang, Q. Rational Design of Novel, Potent Piperazinone and Imidazolidinone BACE1 Inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 3236-3241.
17. (d) Kortum, S. W.; Benson, T. E.; Bielnkowski, M. J.; Emmons, T. L.; Prince, D. B.; Paddock, D. J.; Tomasselli, A. J.; Moon, J. B.; LaBorde, A.; TenBrink, R. E. Potent and Selective Isophthalamide S2 Hydroxyethylamine Inhibitors of BACE1. Bioorg. Med. Chem. Lett. 2007, 17, 3378-3383.
18. (e) Iserloh, U.; Pan, J.; Samford, A. W.; Kennedy, M. E.; Zhang, Q.; Zhang, L.; Parker, E. M.; McHugh, N. A.; Favreu, L.; Strickland, C.;Voigt, J. Discovery of an Orally Efficacious 4-Phenoxypyrrolidine-Based BACE-1 Inhibitor. Bioorg. Med. Chem. Lett. 2008, 18, 418-422.
19. Choi, S.-H;Hur, J.-M.;Yang, E.-J.; Jun,M.; Park, H.-J.; Lee,K.-B.; Moon, E.; Song, K.-S. β-Secretase (BACE1) Inhibitors from Perilla frutescens var acuta. Arch Pharm Res. 2008, 31, 183-187.
20. (b) http://tools.invitrogen.com/content/sfs/manuals/L0724.pdf.
21. Albert, U.; Aguglia, E.; Maina, G.; Bogetto, F. Venlafaxine versus Clomipramine in the Treatment of Obsessive-Compulsive Disorder: A Preliminary Single-Blind, 12-Week, Controlled Study. J. Clin. Psychiatry 2002, 63, 1004-1009. (Pubitemid 35388059)